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effectiveness of a nurse-led palliative care
intervention for HIV positive patients on
antiretroviral therapy: recruitment, refusal,
randomisation and missing data
Keira Lowther1*, Irene J Higginson1, Victoria Simms2, Nancy Gikaara3, Aabid Ahmed4, Zipporah Ali3,
Gaudencia Afuande4, Hellen Kariuki5, Lorraine Sherr6, Rachel Jenkins7, Lucy Selman1 and Richard Harding1Abstract
Background: Despite the life threatening nature of an HIV diagnosis and the multidimensional problems
experienced by this patient population during antiretroviral therapy, the effectiveness of a palliative care approach
for HIV positive patients on ART is as yet unknown.
Findings: A randomised controlled trial (RCT) was conducted in a sample of 120 HIV positive patients on ART in an
urban clinic in Mombasa, Kenya. The intervention was a minimum of seven sessions of multidimensional, person-
centred care, given by HIV nurses trained in the palliative care approach over a period of 5 months. Rates of
recruitment and refusal, the effectiveness of the randomisation procedure, trial follow-up and attrition and extent of
missing data are reported.
120 patients (60 randomised to control arm, 60 randomised to intervention arm) were recruited over 5.5 months,
with a refusal rate of 55.7%. During the study period, three participants died from cancer, three withdrew (two
moved away and one withdrew due to time constraints). All of these patients were in the intervention arm: details
are reported. There were five additional missing monthly interviews in both the control and intervention study arm,
bringing the total of missing data to 26 data points (4.3%).
Discussion: The quality and implications of these data are discussed extensively and openly, including the effect of
full and ethical consent procedures, respondent burden, HIV stigma, accurate randomisation, patient safety and the
impact of the intervention. Data on recruitment randomisation, attrition and missing data in clinical trials should be
routinely reported, in conjunction with the now established practice of publishing study protocols to enhance
research integrity, transparency and quality. Transparency is especially important in cross cultural settings, in which
the sources of funding and trial design are often not based in the country of data collection. Findings reported can
be used to inform future RCTs in this area.
Trial registration: Clinicaltrials.gov NCT01608802.
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Background
Since the advent of ART, and more recently since the
roll out in sub Saharan Africa (SSA), morbidity and mor-
tality of HIV positive people have been transformed [1].
Healthcare which was mostly focused on symptom con-
trol has become focused on virological control, prolong-
ing life and enhancing quality of life for millions of HIV
positive people world-wide including within SSA [2]. At
the end of 2010, 6.65 million people in low and middle
income countries were receiving ART [3]. As inter-
national guidelines change, lowering the CD4 threshold
for initiation, the proportion of patients and thus the
size of the population eligible for ART increases [4,5]. In
Kenya, where this study was conducted, coverage is good
and therefore increasing numbers of patients are on
ART [6]. This means that there is an increasing popula-
tion for whom quality of life is now a focus.
Improving access to ART has required a huge adapta-
tion in health care provision: an emphasis on the
delivery of ART via rural clinics, the integration and
streamlining of services, and investment in minimising
loss to follow up of patients who are eligible for ART
due to the need for high rates of adherence [3]. While
the systemic changes that have come about as a result of
the need to scale-up ART provision are laudable, service
provision amidst the changing nature of the experience
of living with HIV in SSA requires attention.
Although deaths due to AIDS-related illness have de-
creased due to improvements in treatment and many pa-
tients are living longer and in better health, and
although two patients have been functionally cured, HIV
remains an incurable, life-limiting condition [3]. Increas-
ing numbers of patients are living with HIV with multi-
dimensional problems that include physical symptoms,
psychological and spiritual distress as well as social
problems such as isolation and stigma [7-11]. A shift in
the focus of care is required to address patients’ multidi-
mensional needs while continuing to ensure access to
ART, particularly in light of evidence that unaddressed
psychological distress and depression are associated with
non-adherence to ART and treatment failure [12-14].
Palliative care offers a patient centred, holistic ap-
proach to HIV care which aims to improve the quality of
life of patients and their families [15]. It integrates phys-
ical symptom relief with psychological and spiritual as-
pects of care, and is mandated throughout the course of
life threatening illnesses, in conjunction with other therap-
ies intended to prolong life, such as ART [15,16]. Previous
evidence of the effectiveness of a palliative care approach
for HIV has been generated prior to widespread availabil-
ity of ART; therefore, evidence is needed to identify effect-
ive models of holistic care to meet the needs of patients
with HIV on ART and their families [17].We conducted an RCT of a palliative care intervention
for patients with HIV infection established on ART. The
study protocol has been registered and published (Clini-
caltrials.gov no. 6594/3200) [18]. Here we present data
regarding recruitment, refusal to participate, randomisa-
tion, and missing data. This is particularly important in
trial research in cross cultural settings, where there is
potentially a greater need for transparency due to con-
cerns around ethical implementation of trials and risks
of exploitation when conducting research among vulner-
able populations [19].
The trial findings will be reported in a subsequent
publication according to guidance from the Consolidated
Standards of Reporting Trials (CONSORT) [20].
Methods
Study design
TOPCare, (Treatment Outcomes in Palliative Care) is a
mixed method study comprising a randomised con-
trolled trial (RCT) with qualitative interviews among a
subset of the trial sample [18].
Ethics
Ethics approval was obtained from the relevant bodies,
(see section Ethical approval). Participants and their data
were handled in strictest confidence. Study files were
kept securely in a locked cabinet at the study site, separ-
ately from any identifying information.
Participants
Participants were consecutively recruited from the HIV
clinic at the study site. To begin screening, the re-
searcher, using a random number table, selected a num-
ber from within a range corresponding to numbers
allocated to register patients currently in attendance at
the study site. Initial inclusion criteria were: HIV posi-
tive, adult (>18 years old), on ART for more than one
month and cognitively able to consent to participation
in the study. Participants meeting this criteria were then
asked to rate their pain and symptoms on the African
Palliative Care Association African POS (APOS), an out-
come measure validated in sub Saharan Africa [21,22].
Participants reporting 3, 4, or 5 on a 0 (no pain)-5 (over-
whelming pain) point scale that had endured for at least
two weeks were informed about the trial and invited to
participate. They were then taken through the full infor-
mation sheet and consent process in kiSwahili, or
English according to participants’ choice.
Randomisation
After completion of the baseline data collection inter-
view, block randomisation was performed to allocate
participants to control or intervention group. There
were three blocks to ensure an even and manageable
Table 1 Chronology of data collection and delivery of
intervention versus standard care
Study event
Baseline ● ◊ Δ
Within 1 week of first contact ◊
Within 2 weeks of first contact ◊
Month 1 ● ◊ Δ
Month 2 ● ◊ Δ
Month 3 ● ◊ Δ
Month 4 ● ◊ Δ
● = Data collection interview.
◊ = Study nurse session for intervention participants (minimum).
Δ = Clinic nurse session for control participants (minimum).
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after single use) were blindly selected by the researcher
to randomly allocate the participants to a study arm.
Standard best practice
The control participants continued to receive standard
best HIV care at the comprehensive care clinic. This
consisted of nursing or medical assessment, repeat pre-
scription of ART, referrals to ART adherence support,
nutrition support or community support team as appro-
priate. Essential medicines and basic medical care are
free to HIV positive patients.
The intervention
The nurses delivering the intervention volunteered from
the comprehensive care clinic to attend the palliative
care training and temporarily become the study nurses.
This palliative care training comprised two weeks of di-
dactic training and mentoring in palliative care, provided
by trainers from the Kenyan Hospice and Palliative Care
Association (KEHPCA). Intervention participants re-
ceived a minimum of seven appointments with the study
nurse over the four- month course of the study. For each
appointment the components of standard care were de-
livered by the intervention nurses in the clinic in
addition to the palliative care package. In order to re-
duce contamination, the intervention nurses did not
provide standard care to any participants not in the
intervention arm of the study during the trial period.
The palliative nursing assessment was multidimen-
sional, representing the holistic model of palliative care
provision, and was informed by similar assessment pro-
cedures from sub Saharan Africa [15]. Care was deliv-
ered by the study nurses in accordance with the African
Palliative Care (APCA) Standards for providing quality
palliative care [23]. Support and supervision was pro-
vided by the local hospice, which managed complex par-
ticipants with needs beyond the competency of the
study nurses. Participants were also referred to members
of the hospital multidisciplinary team, such as chaplaincy
or nutritional support if appropriate.
Data collection interviews
Interviews were conducted face to face with questions
read aloud and questionnaires completed by a trained
local researcher, to account for low literacy rates among
this population. Interviews were conducted in kiSwahili
or English at monthly intervals for 4 months post base-
line (Table 1).
Outcome measures
We used self report questionnaires to assess patient
outcomes: the A-POS) [21], the Medical Outcomes Study-
HIV (MOS-HIV) [24], the General Health Questionnaire-12 (GHQ-12) [25,26], Client services receipt inventory
(CSRI) [27] and questions about adherence and risk be-
haviours. Decisions about which questionnaires to use
were based on the availability of validation data in similar
populations.
Analysis
Objectives of the analysis were to: 1) examine recruit-
ment flow 2) describe demographic characteristics of the
two trial arms, 3) determine refusal rate, 4) examine the
distribution of patient attrition and missing data. A
CONSORT diagram is presented detailing recruitment
flow, refusal rate and attrition at each monthly time
point [20]. Baseline data were examined for differences
in distribution of variables between intervention and
control groups.
Missing data analysis examined the pattern of missing
data and compared the clinical and demographic charac-
teristics of participants who withdrew prematurely from
the study with the remainder of the sample with com-
plete data.
Sample size
A sample of 120 participants was required to meet the
RCT objectives [18]. Based on the opinion of the study
site clinic manager regarding numbers of participants at-
tending the clinic, it was estimated that the researcher
could recruit one patient meeting the inclusion criteria
per day, and therefore recruitment would last approxi-
mately 6 months.
Results
Recruitment flow
A total of 2070 participants were screened over the re-
cruitment period, which lasted 5.5 months. Of all partic-
ipants who were eligible for the inclusion in the trial,
55.72% refused to consent to participation (n = 151). Of
the screened clinic population who were adult, HIV
positive, 1664/2070 (80.4%) were on ART for more than
one month, 271/1664 (16.3%) reported moderate to
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weeks and 120/271 (44.3%) consented. Data on reasons
for refusal was not formally collected, but informally the
researcher was informed that participants often had dif-
ficulty taking time off work to attend the data collection
interviews.
Randomisation
The remaining 120 consenting participants were rando-
mised to receive either the intervention (n = 60) or the
control (n = 60). Sample characteristics are compared in
Table 2.
On average control arm participants had been diagnosed
and on ART for longer than intervention arm participants.
Baseline outcome data (mental and physical health sum-
mary score from MOS-HIV, GHQ-12 score and A-POS
total score), not reported in Table 2 also indicated an even
distribution across intervention and control study arms.
Trial follow up and attrition
The recruitment and follow up flow of the study partici-
pants is depicted in a CONSORT diagram in Figure 1Table 2 Sample characteristics for whole sample and by cont
Entire sample
Female n (%) 97 (81)
Mean age in years (sd, range) 39 (8.9, 22–64)
Has a partner (% yes) 63
Median no. children (IQR) 2 (1–4)
Median no. financial dependents (IQR) 3 (2–5)
Education
Never been to school 10
<4 yrs of school 3
Primary 76
Secondary 27
Diploma 4
Poverty quintile (5 quantiles of wealth), n (%)
1 26 (22.2)
2 21 (18.0)
3 23 (19.7)
4 24 (20.5)
5 23 (19.7)
Median years since HIV diagnosis (IQR) 3.5 (1.3–5.2)
Median years on ART (IQR) 2.5 (0.8–4.2)
Median CD4 count (cells/mm3, IQR) 358 (223–506)
Receiving TB treatment (% yes) 8
WHO stage
Stage 1 13
Stage 2 41
Stage 3 62
Stage 4 4[20]. Over the trial period there were 6 participants who
prematurely withdrew from the trial, (all allocated to the
intervention arm) representing 5% of the total sample
(n = 120). Three participants died before the trial was
complete, three withdrew prematurely (two moved away
and one became less available due to work commit-
ment). Of those participants who remained alive during
the study period, 98.1% of possible data was obtained.
Missing data
Within the interviews which were attended, there was
only one missing item (omitted or skipped question
within the completed questionnaires). All other attended
interviews had complete data. A total of 26 interviews
were not attended, therefore for these interviews there is
no data for any outcome measure (26 missing interviews
out of a possible total of 600: 4.3% missing). The distri-
bution and time line of this missing data is described in
Table 3.
Whilst the figure of 4.3% missing data is low, of this
4.3%, 21 of the 26 missing interviews (81%) occur in the
intervention arm. The distribution of missed singlerol and intervention study arm at baseline
(n = 120) Control (n = 60) Intervention (n = 60)
49 (82) 48 (80)
40.5 (9.2, 22–64) 38.3 (8.2, 23–60)
60 66.7
2.5 (1–4) 2 (1–4)
4 (3–5.5) 3 (2–5)
6 4
1 2
35 41
17 10
1 3
14 (23.3) 12 (21.1)
9 (15.0) 12 (21.1)
9 (15.0) 14 (24.6)
12 (20.0) 12 (21.1)
16 (26.7) 7 (12.3)
4.7 (2.4–5.7) 2.6 (0.9–4.4)
3.0 (1.6–5.0) 1.6 (0.4–3.5)
343 (209–558) 359 (247–490)
12 5
4 9
22 19
32 30
2 2
Figure 1 CONSORT diagram showing flow of participants through the study.
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vention study arms (five missing single interviews in
each). The remaining missing data is from participants
who missed more than one interview and prematurely
withdrew from the study, who were all in the interven-
tion arm.
The clinical and demographic details of participants
who exited the trial before the final time point areTable 3 Summary of missing interviews by time point and stu
Month 1
Total control missing data 0
Total intervention missing data 3
Cumulative percentage of missing data 2.5%examined in Table 4. The table contains the data for three
participants who died (attrition due to death or ADD) and
two who left the area (attrition at random AaR) [28]. The
remaining participant left the study due to unavailability.
The sub sample of participants who exited before the
final time-point (n = 6) had been diagnosed more re-
cently and had received ART for a shorter time com-
pared with the sample median, but otherwise theredy arm
Month 2 Month 3 Month 4
1 1 3
4 8 6
3.3% 4.7% 4.3%
Table 4 Demographic and clinical characteristics of participants who exited the trail before the final time point
Missing patients number 1 2 3 4 5 6 Whole sample (n = 120)
Reason for exit Deceased Deceased Deceased Withdrew Withdrew Withdrew
Number of data points 1 3 2 3 2 3 5
Gender f f f m f m 80% female
Time since diagnosis (years) 5 <1 <1 <1 <1 <1 Median 3.5 (IQR 1.3–5.2)
Time on ART (years) 5 <1 <1 <1 <1 <1 Median 2.5 (IQR 1.8–4.2)
Poverty quintile
(1 = higher, 5 = lower wealth)
5 3 1 1 4 4 n/a
Receipt of TB treatment no no no no no no 8% yes
CD4 at baseline 358 524 403 473 492 322 Median 358 (IQR 223–506)
Mental health summary score (MHSS) at
baseline (MOS-HIV) (1–100 range)
12.95 36.79 56.80 20.72 48.85 44.78 Median 44.8 (IQR 36.97–53.78)
Physical health summary score (PHSS) at
baseline (MOS-HIV) (1–100 range)
15.38 15.94 47.20 26.49 59.60 58.92 Median 45.57 (IQR 33.51–53.15)
GHQ-12 score at baseline
(Chronic scoring method, 0–12; 12 worst)
11 12 0 8 3 8 Median 6 IQR (3–9)
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these participants and those who remained in the study.
Due to the small numbers, it was not possible to per-
form analysis to identify whether there was any statisti-
cally significant difference between those lost to follow
up and the remainder of the sample.
The minimal amount of missing data is largely due to
the efforts of the researcher, who worked in close collab-
oration with the staff and management at the study site
to contact participants who had not attended their data
collection appointments. Community tracers from the
comprehensive care clinic, usually employed to ensure
adherence to ART, were asked to enquire about partici-
pants who had not attended their appointments using
their contacts and local knowledge. This collaborative
approach contributed to the minimal amount of missing
data and subsequent high quality dataset.
It is important to closely examine the participant data
to identify whether the participants who exited the trial
before the final time point, left or died due to their par-
ticipation in the trial, particularly as those who left pre-
maturely were allocated to the intervention study arm.
We have performed such an examination and are satis-
fied that the attrition and missing data is not due to re-
ceipt of the intervention, as there were extraneous
circumstances in each case. While a detailed report of
each relevant participant would compromise patient
anonymity, the salient points can be summarised as
follows:
Two participants who died in the intervention group
were diagnosed with advanced cervical cancer, one dur-
ing the trial, and one who had previously been diag-
nosed. Management of their cancer was in line with
hospital policy; if eligible for chemotherapy and unable
to afford it, they would both have been able to apply fora hardship fund held by the hospital, ensuring access to
treatment. These participants received education and
counselling on topics such as nutrition, HIV, ART adher-
ence, hygiene and medication side effects in addition to
psychosocial support for themselves and their families.
The additional support they received due to their partici-
pation and allocation to the intervention arm consisted
of pain control medication including opioids, family sup-
port, and information during the dying process.
Three participants migrated before completing the
study. One subsequently died of malaria in the rural area
she had moved to before the study ended. The final pa-
tient who withdrew from the study prematurely became
unavailable due to work commitments.Discussion
This RCT of a nurse-led palliative care intervention is
the first of its kind for HIV positive participants on ART
in the field of palliative care research, and represents an
ambitious attempt to provide evidence of effectiveness
for a holistic approach to the delivery of HIV/ART care
in sub Saharan Africa. In the current climate of ART roll
out in the region, and massive increase in coverage of
access to ART, it is important not to neglect the holistic
needs of the patient, both for patient quality of life and
for efficient and effective adherence to ART.Screening
During recruitment, the inclusion criteria revealed 16.3%
of HIV positive patients on ART attending the clinic had
moderate to severe pain or symptoms. This reflects the
relative physical health of these patients who have been
on ART for more than one month. The relatively strict
inclusion criteria were to identify those in pain or with
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score was the primary outcome of the trial.
Anecdotally the study nurses, on return to their usual
role in the HIV clinic reported that their skills in pallia-
tive care had enabled them to detect high levels of psy-
chosocial distress in many patients. They expressed
surprise that they identified patients in the clinic who re-
ported being physically well, attending only for refill of
their ART prescription, who were found to have severe
unresolved emotional pain.
Consent and refusal
The refusal rate (55.72%) appears to be relatively high
compared with studies in similar populations in Sub
Saharan Africa (30% [29], 12% [30], 3% [31]). A study
conducted in the same region of Kenya as the current
trial explored the concept of informed consent in a trial
with 100% consent rate [32]. The study authors identify
that many participants consent to participation due to
fears of inferior treatment if they refuse. Other reasons
for consenting to participation included participants
who assumed that there would be direct therapeutic
benefit, despite the randomised controlled trial study de-
sign [32]. This paper also reported that if participants
refused to participate, often it was because they antici-
pated little personal therapeutic benefit for the personal
cost to them, either financially or in time [32]. In the
light of these findings, our comparatively high refusal
rate of 55.7% may not be a cause for concern.
The researcher in the TOPCare study was instructed
to guide the participants through the information sheet
slowly, answer questions and to specifically advise partic-
ipants that there would be no consequences for refusal
to participate. She was also instructed to explain clearly
that if the participant was randomised to the control
arm, they would continue to receive the same care in
the clinic as previously but would be expected to attend
five data collection interviews, each lasting approxi-
mately 45 minutes. This could have contributed to the
high refusal rate by ensuring that the participants had a
good understanding of the costs and benefits of partici-
pation, financial and otherwise, and the very real possi-
bility that they may not receive the intervention.
Research into the process of informed consent in
Ethiopia found that having a stigmatising condition re-
duced the likelihood of consent, as participants feared
further stigmatisation as a result of their participation
[33]. Stigmatisation is a major concern for participants
with HIV in Kenya, as documented by the extensive lit-
erature on the subject [34-37]. It is therefore likely to
have contributed to the high refusal rate.
Respondent burden is defined as a subjective phe-
nomenon of physical, psychological or financial hardship
associated with participation in research [38]. Examplesare when questions may be sensitive, stressful to answer
or the process could be demanding in terms of interview
time or frequency. Research fatigue is elsewhere identi-
fied as associated with a lack of practical change seen
resulting from previous research engagements [39]. It is
possible that the participants felt that this research was
too costly, either in terms of time taken, financially due
to missed work opportunities or emotionally due to the
sensitive nature of the subject. It is important to bear in
mind that this study was conducted in an outpatient set-
ting, where participants have roles and responsibilities to
fulfil outside of the study setting. The study site for this
trial is very experienced in conducting research and it is
a possibility that this population are very research expe-
rienced, increasing the chance of respondent burden or
fatigue.
Therefore, high refusal rate in this study could be due
to a combination of the clear explanation of the cost in
terms of patient time and potential lack of benefit if allo-
cated to the control study arm, the stigmatising nature
of HIV and research fatigue. Unfortunately no data were
formally collected on reasons for refusal to participate.
While 55.7% of all eligible participants in the clinic
approached for consent refused to participate, this re-
fusal rate should be examined in the context of the min-
imal attrition and missing data in the dataset from this
trial. It is possible that due to the clear explanation to
participants at consent, participants were aware of the
costs to them and therefore did not consent if they
would be unable to attend and participate fully in the
study. In addition, the researcher paid close attention to
participants who did not attend for interview and went
to great lengths to contact them and encourage them to
participate. Because of the value placed by the study de-
sign team on a clear ethical approach, it was ensured
that participants had access to culturally appropriate
consent materials and a kiSwahilli speaker to discuss the
costs and benefits to the patient in detail. These ele-
ments of the procedure may have inflated the refusal
rate but achieved an ethical recruitment process with
low attrition.
Missing data distribution
There were three patients within the sample who died
during the study period. All had been allocated to the
intervention arm. There are five possible reasons for
this.
The first is that the randomisation procedure was tam-
pered with. In response to these findings, we reviewed
the randomisation procedure with the researcher, and
examined the research and clinical care data for each pa-
tient who withdrew prematurely. Prior to data collection,
the researcher was trained in the importance of the ran-
domisation procedure in gaining good evidence, and
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then advocate for more effective treatment for this pa-
tient group. The researcher was then closely supported,
with weekly monitoring of data throughout recruitment
and randomisation, in addition to a short period of dir-
ect observation. During training, the research team
discussed the difficulties they would face, such as ran-
domisation of sick participants to the control arm, and
through role play researchers were prepared for this
eventuality to prevent compromising the randomisation
process. Thus, we believe that the randomisation pro-
cedure was performed accurately, with no deviation
from protocol.
Another possibility is that the intervention shortened
the lives of participants. Availability of chemotherapy for
cancer care in East Africa is recognised to be inadequate,
primarily due to financial constraints [40]. Whilst there
is a hardship fund available in the hospital for those who
are unable to afford chemotherapy or radiotherapy, this
would not have benefitted our patients with advanced
cancer, regardless of their inclusion in a study. Two were
too advanced in their disease for these therapies to be of
benefit and the third would have not been eligible, be-
cause of his stable financial status. It is of note that since
this research, the hospital has begun a screening
programme for cervical and breast cancer, due to the
high numbers of patients presenting with advanced
disease.
Theoretically it is also possible that intervention pa-
tients were denied some aspect of the care which was
available to control patients; e.g. the pharmacy was
closed by the time they had finished their palliative care
appointment. In reality this did not happen as the pallia-
tive care nurses were extremely diligent at ensuring that
their patients received all that they needed in terms of
nursing care and medical input. They carefully followed
up on results of investigations, and followed up referrals
to physicians, chaplains, imams and hospice.
A third potential reason for a death was that the pa-
tients who disclosed that their husbands were abusive
could have been put in jeopardy, if their husbands dis-
covered that others in authority were aware of the abuse.
However, the nurses were extremely proficient and as a
professional standard, would not disclose this to anyone
outside of the small palliative care team. The team were
in the process of facilitating couples counselling for both
patients who were having difficulties in their marital re-
lationship. Their role was supportive, building the com-
munication skills and confidence of the women in this
situation so they could advocate for themselves and seek
further support if they felt it necessary. As the commu-
nity were able to confirm that the patient with the abu-
sive husband who reportedly died, had travelled to her
family farm, it is not thought that she came to any directharm due to a disclosure of abuse. The other patient
volunteered the information to the study team that she
was migrating to the rural area due to her husband leav-
ing her.
A fourth possible concern was that, as these patients
with severe pain were receiving opioid based analgesia,
which is uncommon in Kenya, they could have received
an overdose, leading to their death. The palliative care
nursing team received intensive support and training in
identifying patients who were in need of opioid anal-
gesia. The hospital did not provide this medication, so it
was provided by the local hospice and supported by their
staff, who carefully monitored each patient closely.
There were only three patients who received opioid an-
algesia during the study period, enabling this to be
closely scrutinised and controlled.
The final option is that all the deaths occurred in the
intervention group by chance.
In our forthcoming report of the study findings, ana-
lysis will be conducted including these participants with
partial data as it is anticipated that due to the low num-
bers, the impact on findings will be minimal.
Randomisation
Because of unreliable internet connectivity at the study
setting, electronic randomisation was not possible. The
randomisation approach that we used appears to have
been effective, with even distribution between study
arms of almost all variables.
It is possible that in the future, recruitment in this
population will remain challenging, as participants see
themselves as healthy because of their ability to be eco-
nomically productive, normalising their pain and symp-
toms. However, these methodological difficulties should
not preclude high quality research, as evidence on the
prevalence of pain, symptoms and psychological distress
in this population, indicate that multidimensional prob-
lems in the participants group continue in the presence
of ART, and should be addressed [7,14,41].
Conclusion and recommendations
In publishing this data, we restate our commitment to
ethics and quality in research, in addition to preparing
the data for analysis of outcomes. Analysis shows full re-
cruitment of the planned sample was successful, with
good retention and minimal attrition. We have estab-
lished that recruitment procedures were appropriately
implemented, missing data is low, and there are few
baseline differences between arms.
In addition, our relatively high refusal rate may indi-
cate that informed consent has taken place, particularly
when accompanied with low participant attrition. This
reflects our commitment to a clear and ethical recruit-
ment procedure.
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ethically conduct an RCT, in a resource-constrained set-
ting with a strong collaborative relationship. We propose
that researchers conducting research in cross cultural
contexts continue to report their experiences in this
way, including difficulties and unexpected findings, to
increase research transparency, integrity and quality and
to allow for better interpretation of the forthcoming out-
come data.
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